|
|
Neelam Azad, Ph.D., Hampton University, Hampton, VA
"My research focuses on exploring the modalities that dictate pathogenesis of pulmonary disorders, particularly lung fibrosis and lung cancer, both diseases that disproportionately afflict minority populations. I am involved in the identification of specific molecular targets and biomarkers for diagnosis and treatment of these diseases. My long-term career goal is to become a successful academician and establish a successful research program dedicated to the investigation of lung pathologies."
Abstract #3072: Synthesis of substituted N-{4-[(2-hydroxyethyl)sulfanyl]-3,6-dihydropyridin-1(2h)-yl} benzamide/benzenesulfonamide as antiinflamatory and anticancer agents
PO.CH01.01. Poster Session - Natural Products
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Mahavir B. Chougule, Ph.D., College of Pharmacy, Unviersity of Hawaii, Hilo, HI
“The long-term goal is to establish the extramurally funded cancer research program; to develop platform targeted nanoparticles for cancer treatment; and involve pharmacy students in cancer research. Professional advancement by achieving tenure and promotion at college to continue my service.”
Abstract #3142: Biocompatible nanocarrier mediated delivery of STAT-6 siRNA to cancer cells.
PO.ET08.01. Poster Session - Genetic Engineering for Cancer Therapy
Tuesday, April 9, 8:00 a.m. - 12:00 p.m.
|
|
|
Vivian Colon, Ph.D., Uniiversity of Puerto Rico, Medical Sciences Campus, San Juan, PR
"My long-term goal is to become an independent investigator, lead a group of researchers in the area of HPV-related cancers and mentor young students in the area of cancer prevention and control."
Abstract #3985: Cancer-related risk factors in Hispanic women in the San Juan metropolitan area of Puerto Rico.
PO.EP01.01. Poster Session - Epidemiology of Breast and Ovarian Cancers
Sunday, April 7, 1:00 p.m. - 5:00 p.m.
|
|
|
Duc P. Do, Ph.D., Chcago State University, Chicago, IL
"I would like to continue my studies which involve anticancer therapies and drug delivery systems. I am particularly interested in research involving nanotechnology and targeted delivery systems. I have had experience with albumin microsphere and nanosphere delivery systems. I am also interested in examining the stability of pharmaceutical products using various analytical techniques (e.g., HPLC, DSC)."
Abstract #737: Formulation of oral microparticulate drug delivery system for cancer.
PO.ET01.05. Poster Session - Antibody Therapeutics and Novel Delivery Technologies
Tuesday, April 9, 1:00 p.m. - 5:00 p.m.
|
|
|
Quentin Felty, Ph.D., Florida International University, Miami, FL
“My long-term research goal is to use my mechanistic research on endocrine disrupting chemicals and oxidative stress to explain how environmental factors contribute to cancer disparity with the hope of controlling cancer in vulnerable communities."
Abstract #1041: PCB153-induced angiogenesis depends on redoxsensitive Pyk2 signaling.
PO.TB05.02. Poster Session - Novel Angiogenic Factors and Emerging Mechanisms
Tuesday, April 9, 1:00 p.m. - 5:00 p.m.
|
|
|
Kevin D. Houston, Ph.D., New Mexico State University, Las Cruces, NM
“My long-term career goal is to develop an internationally recognized research program focused on understanding the molecular mechanisms of steroid hormone signaling in cancer cells. Such a program will increase training opportunities in cancer research for both undergraduate and graduate students at New Mexico State University."
Abstract #7321: Activation of G-protein coupled estrogen receptor (GPER) inhibits ELT-3 uterine leiomyoma cell proliferation.
PO.EN01.01. Poster Session - Preclinical Studies in Hormone-Responsive Cancers
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Efe W. Iyamu, M.D., Meharry Medical College, Nashville, TN
"As a clinician-scientist, my overall career goal is to continue to engage in patient-oriented research that will have a direct impact on patients, especially those patients with inflammation-related diseases that have direct or indirect link with colorectal cancer and other gastrointestinal malignancies."
Abstract #4865: Targeted inhibition of arginase-1 may underline the suppression of the development of colonic neoplasia in a transgenic APC Min mouse model.
PO.EN01.01. Poster Session - Preclinical Studies in Hormone-Responsive Cancers
Monday, April 8, 2013, 1:00 p.m. - 5:00 p.m.
|
|
|
Anand Iyer, Ph.D., Hampton University School of Pharmacology, Hampton, VA
"The primary area of my research interest is cancer cell biology, with specific focus on lung cancer. My research is focused on delineating the signaling pathways involved in the progression of lung cancer. I hope to continue with my pursuit of understanding the basis for the progression of cancer, and hope to develop therapies that may be useful in the clinic. I wish to be involved in academia, balancing my time between basic research and spending my time with students so that I can share my passion for science with them."
Abstract #3072: Antitumorigenic effects of a novel digitoxin analogue.
PO.CH01.01. Poster Session - Natural Products
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Dae J. Kim, Ph.D., University of Texas Health Science Center at San Antonio, Edinburg, TX
"The goal of my research is to understand the functional role of
protein tyrosine phosphatases in the molecular and cellular mechanisms of environmentally-induced carcinogenesis and develop novel potential therapeutic approaches for the prevention of cancer."
Abstract #2452: The role of T-cell protein tyrosine phosphatase (TC-PTP) in UVB-induced epidermal cell proliferation and survival.
PO.CG01.02. Poster Session - Carcinogenesis
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Lilia Kucheryavykh, Ph.D., Universidad Central del Caribe, Bayamon, PR
“My long-term professional goal is to obtain an RO1 grant and to expand my research program at UCC in neuroscience with a focus on the role of the tumor environment on glioma dispersal and proliferation.”
Abstract #3861: Role of monocyte chemotactic protein-1 (MCP-1) in the tumor microenvironment.
PO.TB06.05. Poster Session - Chemokines, Cytokines and Tumor Microenvironment Interaction
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Nazarius S. Lamango, Ph.D., Florida A&M University, Tallahassee, FL
“My long-range objectives are to continue to engage students in innovative methods in cancer research to effectively tackle and understand the molecular mechanisms by which PMPMEase overexpression/hyperactivity interferes with polyisoprenylated protein signaling pathways leading to cancers. Graduate and undergraduate students will remain an intricate part of the research endeavor as they apply, and learn during the process, novel approaches in seeking solutions to the cancer problem by engaging in one of the current or future research areas in the lab. I will also continue to incorporate up-to-date discoveries, methods and therapeutic approaches in my classroom discussions with PharmD students.”
Abstract #1452: Polyisoprenylated methylated protein methyl esterase as a potential therapeutic target and biomarker in lung cancer.
PO.ET03.01. Poster Session - Identification of New Cancer Targets 2
Tuesday, April 9, 1:00 p.m. - 5:00 p.m.
|
|
|
Richard LeBaron, Ph.D., University of Texas at San Antonio, San Antonio, TX
“My long-range goal is to enrich academic support and opportunities for underrepresented minority individuals seeking to pursue professional training and development in biomedical research generally, and obesity-related diseases in cancer and diabetes specifically.”
Abstract #6585: Breast cancer biomarkers from biosimulations: transcriptome-to-reactome™ technology.
PO.MCB14.01. Poster Session - Integrative and Computational Cancer Biology
Wednesday, April 10, 8:00 a.m. - 12:00 p.m.
|
|
|
Magaly Martinez-Ferrer, Ph.D., University of Puerto Rico, San Juan, PR
“I recently obtained one of my goals that was to get a tenure-track faculty position. My goal is to be an independent funded investigator and establish an urological cancer research program at my institution.”
Abstract #6241: CCL4 alters migration and induces the expression of alpha smooth muscle actin.
PO.TB06.05. Poster Session - Chemokines, Cytokines and Tumor Microenvironment Interaction
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Manoj K. Mishra, Ph.D., Alabama State University, Montgomery, AL
“My long-term career objectives and research goals are to reduce health disparities in cancer and to elucidate the molecular mechanism involved during prostate cancer progression and clearance."
|
|
|
Ana P. Ortiz Martinez, Ph.D., University of Puerto Rico Comprehensive Cancer Center, San Juan, PR
“My long-term career goal is to become an R01 level independent cancer researcher, and help promote the well-being of Hispanic populations, with a focus on health disparities and cancer prevention and control. In the future, I would also like to be the director of a cancer control and population sciences program at a comprehensive cancer center.”
Abstract #2361: Factors associated to concurrent anal and cervical HPV infection: Results from a population-based study among Hispanics.
PO.EP01.03. Poster Session - Epidemiology of Genitourinary and Lung
Tuesday, April 9, 1:00 p.m. - 5:00 p.m.
|
|
|
Sederick C. Rice, Ph.D., University of Arkansas at Pine Bluff, Pine Bluff, AR
“My long-range career objectives are to become a hypothesis-driven, externally funded cancer researcher and study the development and progression of primary tumors into metastatic cancers using translational bioinformatics and pharmacogenomics. My research goals are to use translational bioinformatics to assess the rates of metastasis in primary tumors, correlate treatment therapies that promote the progression of primary tumors into metastatic cancers using translational bioinformatics and pharmacogenomics, and use translational bioinformatics and pharmacogenomics data to develop more effective individualized cancer treatment protocols."
|
|
|
Checo J. Rorie, Ph.D., North Carolina Agricultural and Technical State University, Greensboro, NC
“Our lab is interested in finding biomarkers for the triple-negative breast cancer subtype in order to develop targeted therapy and treatment."
Abstract #7526: Apogossypolone derivative -BI97D6 effectively targets MCL1 overexpressing Acute Myeloid Leukemia cells.
PO.MCB02.04. Poster Session - Cell Death and Cancer Therapy
Sunday, April 7, 2013 1:00 p.m. - 5:00 p.m.
|
|
|
Anjana D. Saxena, Ph.D., City Univesrity of New York Brooklyn College, New York, NY
"My long-term research goal is to define the roles of nucleolar stress-responsive proteins in regulating cell proliferation, growth (size) and death pathways with the potential to identify the molecules of therapeutic values. My goals are also to continue training undergraduates/graduates and develop their interests in basic or translational cancer research through teaching as well as laboratory research experiences.
Abstract #4881: Nucleolin phosphorylation mediated regulation of gene expression in determining cellular fate during the DNA damage response (DDR).
PO.MCB05.01. Poster Session - Post-Transcriptional Regulation of Gene Expression
Tuesday, April 9, 8:00 a.m. - 12:00 p.m.
|
|
|
Anil Shanker, Ph.D., Meharry Medical College, Nashville, TN
“The long-term goal of the applicant PI's research is to investigate the immune mechanisms of tumor surveillance and rejection and to develop immunotherapy approaches that provide durable clinical benefits in cancer patients including minority populations."
Abstract #7316: Resuscitating immune surveillance in cancer.
PO.IM02.05. Poster Session - Immune Therapies: Adoptive Cellular Therapies and Combinations
Tuesday, April 9, 1:00 p.m. - 5:00 p.m.
|
|
|
Zaki A. Sherif, M.D., Ph.D., Howard University, Washington, D.C.
“My long-term research goal is to study the biological mechanisms of germ-line mutation and its contribution to carcinogenesis and tumorigenesis in breast cancer. My career goal is, using a translational research approach, to advance the results of cancer research into the clinics. Such a need is especially pressing in neglected communities where patients participate in many clinical and epidemiological research studies but there are no reciprocal medical benefits provided for them except to state that their contributions help humanity in its fight against cancer. My immediate career goal is to secure funding from the NIH and national agencies to support my research and with my advance to independent researcher secure a tenured faculty position."
Abstract #1435: Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni Syndrome and human cancer cell lines.
PO.MCB04.02. Poster Session - Non-p53 Tumor Suppressors
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Shailesh Singh, Ph.D., Morehouse School of Medicine, Atlanta, GA
“My long-range objectives and research goals are to develop comprehensive therapeutic and preventive strategies directed to the tumor as well as immune cells."
Abstract #1828: Differential expression of CC chemokine receptor-9 in prostate cancer.
PO.TB04.09. Poster Session - Tumor Metastasis: Quantification and Biology
Wednesday, April 10, 8:00 a.m. - 12:00 p.m.
|
|
|
Rajesh Singh, Ph.D., Morehouse School of Medicine, Atlanta, GA
"My long-term research interest is to develop therapeutic and chemo-preventive strategies for cancer using synthetic and natural agents."
Abstract #2437: Targeted delivery of resveratrol to improve therapeutic outcome in prostate cancer.
PO.CH06.01. Poster Session - Drug Delivery Technology
Tuesday, April 9, 1:00 p.m. - 5:00 p.m.
|
|
|
Chung Song, Ph.D., UT Health Science Center at San Antonio, San Antonio, TX
“My CV shows my commitment to cancer research. During all these years, I have mostly worked on prostate cancer and the effect of androgen receptor signaling pathway of tumor growth and progression. At this point, I have come with an interesting idea that, if being true, can make an answer to many questions in AR signaling pathway. Right now, I am working on that hypothesis. In addition, I have trained many students and M.D.s in our lab and I have the major responsibly to be sure that they are highly trained in lab skills. Many of them are involved in cutting-edge cancer researches in different institutions all over the world. Beside mentoring and training the students, I have collaborated in five different projects in our lab that are going to be submitted for publication this year.”
Abstract #2262: Loss of steroid sulfotransferase (SULT) in human prostate cancer: Potential implications for SULT as a biomarker and therapeutic target
PO.MCB03.01. Poster Session - Molecular Marker Studies
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
|
|
Rajeshwar R. Tekmal, Ph.D., University of Texas Health Science Center at San Antonio, San Antonio, TX
“My goal is to take the use of estrogen receptor beta agonist to clinical trials and test their use in endocrine therapy sensitive and resistant breast cancers and as well as identify biomarkers of therapeutic response.”
Abstract #6405: The estrogen receptor β agonists, Liquiritigenin and S-equol, inhibit breast cancer cell proliferation through the activation of tumor-suppressor and other pathways.
PO.EN01.01. Poster Session - Preclinical Studies in Hormone-Responsive Cancers
Monday, April 8, 1:00 p.m. - 5:00 p.m.
|
| |
Back to top |